Physiological uptake patterns of gastric lymph node stations on 68Ga-pentixafor positron emission tomography (PET): station-specific patterns to aid interpretation Authors: Yuheng Zou, Hui Wang, Rong Tian, Minggang Su Published: 2026 ABSTRACT AbstractBackgroundThe C-X-C motif chemokine receptor 4 (CXCR4)-targeted tracer, 68Ga-pentixafor, has shown promise for imaging hematologic malignancies including mucosa-assisted lymphoid tissue (MALT) lymphoma involving lymph nodes (LNs). Its physiological uptake patterns in gastric LN stations remain undefined. This retrospective study aimed to evaluate gastric LN positivity in individuals without known malignancy, establish region-specific references, and explore factors influencing uptake.MethodsData of patients with hyperaldosteronism who underwent 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) or PET/magnetic resonance (MR) were retrospectively analyzed. Gastric LNs were categorized as perigastric [1–6], near-extragastric [7–9], far-extragastric [10–12], and distant [13–16]. Positive LNs were those with increased 68Ga-pentixafor uptake which was higher than that of the blood pool. Reference ranges for maximum standardized uptake value (SUVmax) and LN-to-blood pool SUV ratio (LBR) of each LN station were established. Laboratory data including complete blood count, liver function, hepatitis B virus (HBV) serology, and derived inflammatory indices, were analyzed to identify factors associated with tracer uptake.ResultsA total of 122 patients were included. Physiologically increased uptake was rare in perigastric LNs, only one (0.8%) in LN station 3. In near-extragastric groups, 8a (43.4%) and 8p (22.1%) showed notable uptake. Among far-extragastric LNs, LN station 12p had the highest positivity (86.1%), with a median SUVmax of 4.16 and a LBR of 2.23, respectively. LN station 16a2 had a moderate positivity rate (20.5%). Correlation analysis indicated correlation between the LBR in extragastric groups (LN station 9, 12a, 12b, and 12p) and liver function test parameters (P<0.05), while distant LNs uptake showed no significant laboratory associations except that with alanine aminotransferase (ALT).ConclusionsPhysiological 68Ga-pentixafor uptake in gastric LNs is station-specific, notably high in 12p, 8a, and 8p. LN evaluation should integrate uptake and morphology, and larger studies comparing benign and malignant cases are warranted.Keywords: 68Ga-pentixafor, positron emission tomography/computed tomography (PET/CT), positron emission tomography/magnetic resonance (PET/MR), gastric lymph node stations (gastric LN stations), physiological uptake patterns Introduction The C-X-C motif chemokine receptor 4 (CXCR4), a homeostatic receptor, is elevated in various malignant diseases, including mucosa-assisted lymphoid tissue (MALT) lymphoma, multiple myeloma, and solid tumors such as adrenocortical carcinoma and neuroendocrine neoplasms (1). The CXC motif chemokine ligand 12 (CXCL12)/CXCR4 pathway is involved in tumor progression, angiogenesis, and metastasis (2). Besides, CXCR4 is expressed on multiple cell types, including lymphocytes, hematopoietic stem cells, endothelial and epithelial cells and is involved in inflammatory process including immune cells recruitment, migration and infiltration (3-5). A CXCR4-targeting tracer, 68Ga-pentixafor, has emerged as a promising diagnostic tool in evaluating CXCR4-positive diseases mentioned above (6,7). MALT lymphoma, most frequently localized in the stomach, can involve regional lymph nodes (LNs) and disseminate to other sites (8,9). Accurate systemic assessment is therefore essential for disease management. Current guidelines note limited application of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for MALT lymphoma due to variable 18F-FDG avidity, with reported detection rates of 50–60%, which reduces its reliability for staging and response assessment (10). Recent studies demonstrate evidence that 68Ga-pentixafor PET yields superior lesion detection rates in patients with MALT lymphoma, compared with conventional imaging modalities and 18F-FDG PET/CT, although the tracer remains investigational (11-13). Besides, accurate evaluation of LN involvement remains critical for both treatment planning and response evaluation (14). However, physiological uptake patterns of gastric LN stations on 68Ga-pentixafor PET remain poorly characterized. The lack of comprehensive data on physiological distribution poses significant challenges for accurate interpretation of LN involvement, potentially leading to both false-positive and false-negative assessments. Our clinical observations revealed increased abdominal LNs 68Ga-pentixafor uptake in patients with hyperaldosteronism, prompting systematic evaluation of gastric LNs uptake patterns in non-malignant conditions (15,16). We aimed to characterize the biodistribution of 68Ga-pentixafor in abdominal LNs and establish the station-specific physiologic reference ranges. Furthermore, we investigated the potential factors influencing uptake of 68Ga-pentixafor, including inflammatory indices and liver function tests. We present this article in accordance with the STROBE reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-2025-aw-2367/rc). Methods Study participants Consecutive patients who underwent 68Ga-pentixafor PET/CT or PET/magnetic resonance (MR) at West China Hospital, Sichuan University were retrospectively enrolled in this study from Jan 2023 to Feb 2024. The inclusion criterion was hypertension due to hyperaldosteronism. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the ethics board of West China Hospital, Sichuan University (Ethics No. 2020[1670]). Informed consent was waived in this retrospective study. The exclusion criteria were: (I) a history of malignancy or suspected malignancy at the time of examination; (II) age less than 18 years old; (III) known lymphoproliferative disorders; (IV) active systemic inflammatory or infectious disease. Patients were screened through medical history interviews, existing clinical records, and available imaging to exclude known or suspected malignant, hematologic, or active inflammatory conditions. As an exploratory study, no formal sample size calculation was performed. The sample size was selected to evaluate general imaging trends, and reported P values are intended for exploratory purposes. Laboratory evaluation Laboratory parameters, including complete blood count (CBC), liver function tests and inflammatory biomarkers [C-reactive protein (CRP) and interleukin-2 receptor (IL-2R)] were obtained within two weeks before or after the PET scan. Hepatitis B virus (HBV) serological indicators [hepatitis B surface antigen (HBsAg), surface antibody (HBsAb), e antigen (HBeAg), e antibody (HBeAb), core antibody (HBcAb)] were obtained within 3 months before or after the PET scan. CBC associated inflammatory indices were calculated: monocyte-to-lymphocyte ratio (MLR), systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Abnormalities in liver function tests were defined as aspartate aminotransferase (AST) level >40 U/L, alanine aminotransferase (ALT) level >50 U/L, total bilirubin (TBIL) level >10.5 μmol/L, gamma-glutamyl transferase (GGT) >60 U/L, alkaline phosphatase (ALP) level >125 U/L, and/or albumin <40 g/L, based on laboratory data within the hospital (17,18). PET imaging acquisition The radiolabeling of 68Ga-pentixafor was performed as previously reported in a good manufacturing practice (GMP) environment and according to the manufacturer’s instructions (19). No specific patients’ preparation was required before 68Ga-pentixafor injection. 68Ga-pentixafor was administered at a median dose of 137 MBq (range, 71–245). PET/CT or PET/MR scans were obtained 1 h after injection of the radiotracer. PET images were acquired in 3D mode (matrix: 192´192), with acquisition times of 3 minutes/bed position for PET/CT and 6 minutes/bed position for PET/MR. PET/CT scans were performed using an integrated PET/CT scanner (uMI780, United Imaging Healthcare, Shanghai, China). PET/MR scans were acquired using a hybrid PET/MR scanner (SIGNA, GE Healthcare, USA). PET data were reconstructed using comparable reconstruction frameworks for both modalities, including time-of-flight (TOF), point spread function (PSF) modeling, and scatter correction, based on an ordered-subsets expectation maximization (OSEM) algorithm. Reconstruction parameters were 2 iterations with 20 subsets for PET/CT and 2 iterations with 28 subsets for PET/MR. For PET/MR, attenuation correction was performed using a Dixon-based four-compartment MR attenuation model (air, lung, fat, and soft tissue). A Gaussian filter with a 5-mm full width at half maximum (FWHM) was applied for image smoothing. Image analysis Two nuclear medicine physicians independently reviewed the images, and in cases of uncertainty or disagreement, a senior nuclear medicine physician was consulted for consensus interpretation. To better illustrate the distribution of abdominal LNs, LN stations 1–16 were defined according to American Joint Committee on Cancer (AJCC) and Japanese Gastric Cancer Association (JGCA) gastric cancer guidelines (Table S1) (20). Regional LNs was divided into perigastric group (station 1–6) and extragastric group (station 7–12). The extragastric group was further subdivided into the near-extragastric (station 7–9) and far-extragastric (station 10–12) groups. While LN stations 13–16 were classified as distant LNs. Blood pool maximum standardized uptake value (SUVmax) was measured within the thoracic aorta according to the guideline (21). The SUVmax of each LN station was recorded for subsequent analysis. Positivity was defined as increased uptake higher than the blood pool. A semiquantitative target lesion analysis was conducted [LN-to-blood pool SUV ratio (LBR)]. It was calculated as the LNs SUVmax normalized to blood pool SUVmax: Where x is the number of gastric LN station. For negative LNs or no identifiable LNs, the SUV is defined as the blood pool SUV for the station. Morphological characteristics of LNs were screened on axial CT images or MRI images, long-axis diameter (LAD) and short-axis diameter (SAD) of LNs were recorded. LNs were considered enlarged when the SAD exceed 10 mm or/and LAD exceed 15 mm (22,23). Statistical analysis Statistical analysis was performed using SPSS (Version 27, IBM) and R software (version 4.0.5). Continuous variables were assessed for normality using the Kolmogorov-Smirnov test and reported as mean ± standard deviation (SD) for normally distributed data or median [interquartile range (IQR)] for non-normally distributed. The reference ranges of SUVmax and LBR of each LN station were defined by 2.5th–97.5th percentiles (24). The Mann-Whitney U test was used to compare continuous variables between two independent groups, while the Fisher’s exact test or χ2 test was used to analyze categorical variables, including HBV serological indicators. Associations between PET-derived parameters and laboratory variables (including liver function tests and inflammatory indices) were evaluated using Spearman rank correlation analysis. To account for multiple comparisons and control the false discovery rate, P values were adjusted using the Benjamini-Hochberg procedure. All tests were two-tailed with α=0.05 defining statistical significance. For missing data, analyses were conducted using a complete-case approach, excluding cases with missing data for specific analyses. Results Patient characteristics A total of 136 patients were screened. Of the 136 patients, three with multiple myeloma, ten with thyroid carcinoma and one with renal cell carcinoma were excluded, in accordance with the predefined exclusion criteria described in the Methods section. This retrospective analysis included 122 patients [48 male (39.3%), 74 female (60.7%); mean age 50±11.4 years; range, 23–76 years] who underwent 68Ga-Pentixafor PET imaging (93 PET/MR, 29 PET/CT) to lateralize sources of hyperaldosterinism (Figure 1). Flow chart for patient selection. CBC, complete blood count; PET, positron emission tomography. Uptake characteristics of gastric LNs Table 1 summarizes patient-based uptake patterns in regional and distant LNs. Among the 122 patients, 46 (37.7%) had positive regional LNs only, 2 (1.6%) had positive distant LNs only, 65 (53.3%) had both regional and distant LN positivity. Table 1Patient-based uptake patterns of regional and distant lymph nodesDistant LN statusRegional LN statusNegativePositiveNegative9 (7.4%)46 (37.7%)Positive2 (1.6%)65 (53.3%)LN, lymph node. Patient-based uptake patterns of regional and distant lymph nodes LN, lymph node. Station-based analysis further evaluated the distribution and characteristics of positive LNs (Figure 2, Table 2). In perigastric LN stations [1–6], increased uptake was rare, observed only at station 3 (0.82%, 1/122). Among near-extragastric LN stations [7–9], the rate of positivity is relatively high in LN station 8a (43.44%, 53/122), followed by LN station 8p (22.13%, 27/122). LN enlargement was observed in 16.7% of positive LN station 8a cases (Figure 2, Table 2). Figure 3 shows a representative patient with positive 68Ga-pentixafor uptake at LN station 8a. In the far-extragastric LN stations [10–12], LN station 12p exhibited the highest positivity rate of 86.07% (105/122) with an SUVmax of 3.96 (3.26–4.72). Notably, positive LNs at station 12p exhibited an SUVmax of 4.16 (3.48–4.93), with enlargement observed in 58.5% of positive cases. Figure 4 shows a representative patient with positive 68Ga-pentixafor uptake at LN station 12p. In the distant group (LN station 13–16), LN station 16a2 has a moderate positivity rate at 20.49% (25/122). LN enlargement was uncommon in positive other LN stations outside of 8a and 12p. Besides, no enlarged LNs with negative uptake were identified. Distributions of positive gastric lymph node stations. The annotated boxes indicate the lymph node station names along with their respective positivity rates. AA, abdominal aorta; CHA, common hepatic artery; LGA, left gastric artery; PV, portal vein; SA, splenic artery; SMA, superior mesenteric artery; SMV, superior mesenteric vein; SV, splenic vein. Table 2Characteristics of lymph node stations with increased uptake of 68Ga-pentixaforLN station numbern†SUVmaxLBR% enlarged by size criteriaLAD‡ (mm)SAD‡ (mm)10NANANANANA20NANANANANA31NANANANANA40NANANANANA50NANANANANA60NANANANANA734.06 (2.99–4.45)1.67 (1.47–2.20)0%NANA8a533.99 (3.37–4.80)1.76 (1.50–2.21)16.67% 16.00 (15.10–16.75)6.60 (5.70–9.75)8p273.56 (3.20–4.07)1.68 (1.44–1.94)7.14%14.05 (12.70–15.40)8.48 (6.90–10.05)933.39 (3.19–3.79)1.25 (1.19–1.56)NANANA100NANANANANA1134.17 (3.64–4.28)1.24 (1.16–1.76)NANANA12a193.56 (3.34–4.29)1.79 (1.33–2.00)0%NANA12b103.67 (3.30–4.41)1.97 (1.61–2.15)0%NANA12p1054.16 (3.48–4.93)1.91 (1.62–2.33)58.49%19.60 (16.80–24.70)5.35 (4.40–6.70)1324.78 (4.08–5.48)2.23 (2.15–2.31)NANANA140NANANANANA150NANANANANA16a143.79 (3.02–4.62)1.91 (1.39–1.95)NANANA16a2252.96 (2.54–3.46)1.27 (1.07–1.48)NANANA16b1133.16 (2.77–3.90)1.46 (1.25–1.71)NANANA16b2113.41 (2.73–4.50)1.43 (1.27–2.06)NANANAData are presented as median interquartile range, number, or percentage, unless otherwise specified. †, measurements from only positive LNs demonstrating increased 68Ga-pentixafor uptake, defined as LN SUVmax higher than the blood pool; ‡, size was measured only for enlarged LNs. LAD, long-axis diameter; LBR, lymph node-to-blood pool ratio; LN, lymph node; NA, not available; SAD, short-axis diameter; SUVmax, maximum standardized uptake value. Characteristics of lymph node stations with increased uptake of 68Ga-pentixafor Data are presented as median interquartile range, number, or percentage, unless otherwise specified. †, measurements from only positive LNs demonstrating increased 68Ga-pentixafor uptake, defined as LN SUVmax higher than the blood pool; ‡, size was measured only for enlarged LNs. LAD, long-axis diameter; LBR, lymph node-to-blood pool ratio; LN, lymph node; NA, not available; SAD, short-axis diameter; SUVmax, maximum standardized uptake value. 68Ga-pentixafor PET/MR in a 61-year-old woman with hyperaldosteronism. The LN station 12p lymph node (11.0×7.0 mm) located in the hepatoduodenal ligament adjacent to the portal vein (A, C, yellow arrows) appears morphologically normal on axial T2-weighted MR (A, red arrow) but shows elevated tracer uptake (SUVmax 4.93; B, C, red arrows). LN, lymph node; PET/MR, positron emission tomography/magnetic resonance; SUV, standardized uptake value; SUVmax, maximum standardized uptake value. 68Ga-pentixafor PET/MR in a 38-year-old man with hyperaldosteronism. The LN station 8a lymph node (12.6×6.1 mm) located anterior to the common hepatic artery (A, C, yellow arrows) appears non-enlarged on axial T2-weighted MR (A, red arrow) yet demonstrates marked radiotracer accumulation on PET (SUVmax 5.18; B, C, red arrows). PET/MR, positron emission tomography/magnetic resonance; SUV, standardized uptake value; SUVmax, maximum standardized uptake value. To ensure the comparability of data obtained from different imaging platforms, SUVmax values of each LN station were compared between PET/CT and PET/MR, which showed no statistically significant differences between the two modalities (Table S2). Table 3 summarizes measurements from all predefined LN stations across the entire cohort (n=122), including LNs without increased uptake. The corresponding reference ranges of each group (SUVmax and LBR) were derived exclusively from the current cohort. Among these, the far-extragastric group shows the highest reference values, with SUVmax ranging from 1.14 to 5.55 and LBR ranging from 1.00 to 2.92. Table 3Characteristics of lymph node stationsLN groupLN station numberSUVmaxLBRReference of SUVmaxReference of LBRPerigastric groups12.15 (1.92–2.39)1.00 (1.00–1.00)1.11–3.271.00–1.0022.15 (1.92–2.39)1.00 (1.00–1.00)32.15 (1.91–2.39)1.00 (1.00–1.00)42.15 (1.92–2.39)1.00 (1.00–1.00)52.15 (1.92–2.39)1.00 (1.00–1.00)62.15 (1.92–2.39)1.00 (1.00–1.00)Near-extragastric72.18 (1.93–2.44)1.00 (1.00–1.00)1.14–5.261.00–2.558a2.47 (2.10–3.91)1.00 (1.00–1.66)8p2.31 (1.97–2.90)1.00 (1.00–1.00)92.15 (1.92–2.42)1.00 (1.00–1.00)Far-extragastric102.15 (1.92–2.39)1.00 (1.00–1.00)1.14–5.551.00–2.92112.16 (1.92–2.40)1.00 (1.00–1.00)12a2.21 (1.95–2.67)1.00 (1.00–1.00)12b2.15 (1.94–2.49)1.00 (1.00–1.00)12p3.96 (3.26–4.72)1.82 (1.46–2.20)Distant132.15 (1.89–2.40)1.00 (1.00–1.00) 1.11–3.930.92–1.83142.15 (1.92–2.39)1.00 (1.00–1.00)152.15 (1.92–2.39)1.00 (1.00–1.00)16a12.15 (1.46–2.40)1.00 (1.00–1.00)16a22.18 (1.91–2.54)1.00 (1.00–1.00)16b12.32 (2.03–3.08)1.00 (1.00–1.34)16b22.15 (1.89–2.46)1.00 (1.00–1.00)Measurements from all predefined LN stations across the entire cohort (n=122), including LNs without increased uptake. Data are presented as median interquartile range, unless otherwise specified. LBR, lymph node-to-blood pool ratio; LN, lymph node; SUVmax, maximum standardized uptake value. Characteristics of lymph node stations Measurements from all predefined LN stations across the entire cohort (n=122), including LNs without increased uptake. Data are presented as median interquartile range, unless otherwise specified. LBR, lymph node-to-blood pool ratio; LN, lymph node; SUVmax, maximum standardized uptake value. Correlation of 68Ga-pentixafor uptake for gastric LNs and laboratory parameters In the cohort of 78 patients with available liver function test data, elevation of ALT and AST was observed in 6.4% (5/78) and 5.1% (4/78), respectively. All cases of AST elevation (100%, 4/4) and the majority of ALT elevations (80.0%, 4/5) were mild, with values remaining below twice the upper limit of normal (ULN). Besides, elevation of TBIL level (5.1%, 4/78), ALP level (6.4%, 5/78), GGT level (11.5%, 9/78) and reduction of albumin level (19.2%, 15/78) were observed. No correlation between LBR and liver function test data was observed (Figure S1). Among 84 patients with available hepatitis B serology results, six patients (7.1%) were HBsAg positive and 46 patients (54.8%) were HBcAb positive. The prevalence of HBsAg positivity showed no significant differences between perigastric LN-negative and -positive groups (0/1 vs. 6/83, P=1.000), nor between positive and negative groups for near-extragastric (3/27 vs. 3/57, P=0.381), far-extragastric (0/12 vs. 6/72, P=0.587), or distant LNs (4/41 vs. 2/43, P=0.427). Similarly, HBcAb positivity rates did not differ significantly between perigastric LN-negative and -positive groups (47/83 vs. 0/1, P=0.440), or between positive and negative groups for near-extragastric (11/27 vs. 36/37, P=0.053), far-extragastric (6/12 vs. 41/72, P=0.654), or distant LNs (24/41 vs. 23/43, P=0.641). CBC results were available for 77 patients, allowing for the calculation of inflammatory indices. No correlation between LBR and inflammatory indices was observed (Figure S1). Regarding other inflammatory biomarkers, CRP levels were available for two patients. IL-2R was reported in nine patients, with a mean value of 435.22±135.22 (range, 283.00–689.00), and were elevated in two patients. Given the very small subgroup sizes, further analyses of CRP and IL-2R were not conducted. Laboratory parameters comparisons between LNs with different uptake characteristics We compared the laboratory parameters between groups with and without distant LNs uptake (Table 4). In group with distant LNs uptake, patients exhibited higher ALT level (P=0.038). There were no differences between two groups as for other liver function test indexes and inflammatory indices derived from CBC results. Table 4Laboratory parameters comparisons between distant lymph nodes negative group and positive groupLaboratory parametersPDistant LN negativeDistant LN positiveAST (U/L)0.06616.00 (14.00–19.50)17.00 (15.00–24.50)ALT(U/L)0.03814.00 (11.00–18.00)18.50 (12.00–25.75)AST/ALT0.2311.08 (0.94–1.38)1.00 (0.74–1.25)TBIL (μmol/L)0.44412.00 (8.35–16.05)10.70 (8.88–13.63)DBIL (μmol/L)0.4543.10 (2.30–4.45)2.80 (2.30–4.05)ALP (U/L)0.18269.09±18.3175.68±20.41Albumin (g/L)0.38441.53±2.7942.39±3.21GGT (U/L)0.17218.00 (10.00–27.00)18.50 (13.00–40.00)MLR0.6170.26 (0.19–0.34)0.25 (0.21–0.28)SIRI0.6910.79 (0.62–1.37)0.85 (0.64–1.30)SII0.706433.72 (345.14–564.73)401.72 (311.23–622.25)PIV0.540154.58 (113.85–259.85)179.54 (120.83–293.00)NLR0.3072.06 (1.81–2.79)1.90 (1.63–2.54)PLR0.142134.40 (113.96–168.02)109.43 (97.75–156.20)PAR0.5204.85 (3.90–5.49)5.06 (4.30–5.84)Data are presented as mean ± standard deviation or median interquartile range for normally and non-normally distributed data, respectively, unless otherwise specified. MLR, SIRI, SII, PIV, NLR, PLR, and PAR were analyzed in distant LN-negative (n=36) and distant LN-positive (n=41) groups. AST, ALT, AST/ALT, TBIL, DBIL, ALP, Albumin, and GGT were analyzed in distant LN-negative (n=35) and distant LN-positive (n=47) groups. All comparisons were performed using the Mann-Whitney U test. ALP, alkaline phosphatase; ALT, lanine aminotransferase; AST, aspartate aminotransferase; DBIL, direct bilirubin; GGT, gamma-glutamyl transferase; MLR, monocyte-to-lymphocyte ratio; LN, lymph node; NLR, neutrophil-to-lymphocyte ratio; PAR, platelet-to-albumin ratio; PIV, pan-immune-inflammation value; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; TBIL, total bilirubin. Laboratory parameters comparisons between distant lymph nodes negative group and positive group Data are presented as mean ± standard deviation or median interquartile range for normally and non-normally distributed data, respectively, unless otherwise specified. MLR, SIRI, SII, PIV, NLR, PLR, and PAR were analyzed in distant LN-negative (n=36) and distant LN-positive (n=41) groups. AST, ALT, AST/ALT, TBIL, DBIL, ALP, Albumin, and GGT were analyzed in distant LN-negative (n=35) and distant LN-positive (n=47) groups. All comparisons were performed using the Mann-Whitney U test. ALP, alkaline phosphatase; ALT, lanine aminotransferase; AST, aspartate aminotransferase; DBIL, direct bilirubin; GGT, gamma-glutamyl transferase; MLR, monocyte-to-lymphocyte ratio; LN, lymph node; NLR, neutrophil-to-lymphocyte ratio; PAR, platelet-to-albumin ratio; PIV, pan-immune-inflammation value; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; TBIL, total bilirubin. Discussion Although 68Ga-pentixafor is still an investigational tracer for myeloma and lymphoma imaging, it has emerged as a valuable tool in both benign and malignant diseases. As 68Ga-pentixafor may yield false positive abdominal LNs findings in patients scanned for oncological purposes, establishing physiological uptake patterns of gastric LNs in non-malignant conditions is critical to enable accurate interpretation of LN involvement and to maximize its potential clinical utility (6,12,25). To the best of our knowledge, this presents the first study to comprehensively evaluate physiological uptake patterns of gastric LN stations using 68Ga-pentixafor PET and to establish region-specific reference ranges of SUVmax and LBR for these regions. In this study, our quantitative analysis established upper reference limits for SUVmax (<3.27, <5.26, <5.55, and <3.93) and LBR (<1.00, <2.55, <2.92, and <1.83) in perigastric, near-extragastric, far-extragastric, and distant LN groups respectively. These reference values may help distinguish physiological from pathological uptake and could provide preliminary guidance for LN assessment and interpretation. Establishing region-specific reference ranges is clinically important for accurate interpretation of LN involvement because uptake patterns vary by anatomical region. Perigastric LN stations [1–6] exhibit a relatively low positivity rate and LBR value among patients with non-malignant disease, suggesting that increased 68Ga-pentixafor uptake in these regions among patients with MALT lymphoma is likely disease-specific, where these LNs are frequently affected in MALT lymphoma patients (26,27). In contrast, extragastric LN stations [7–12] show higher uptake frequencies and LBR values, with the highest frequencies observed at LN station 12p, followed by 8a and 8p. Notably, LN station 12p demonstrates uptake in 86% of patients, suggesting that this may represent a common physiological and systemic finding rather than pathological involvement. Except for LN station 7, a common site of MALT lymphoma involvement, which demonstrated a low positivity rate (2.46%) in a condition without known malignancy, highlighting the diagnostic significance of abnormal uptake in this region (28). Besides, enlargement of positive LNs in these three LN stations (12p, 8a and 8p) was observed, especially at LN station 12p (58.5%). Previous studies also reported that enlarged LNs in these regions can be detected on conventional imaging in healthy subjects, likely reflecting reactive or non-malignant changes (29,30). While no morphologically enlarged LNs were identified radiographically in other positive LN stations. Therefore, when interpreting 68Ga-pentixafor findings, both uptake activity and morphological characteristics should be integrated for accurate clinical assessment. Especially for LN station 12p, a more flexible criteria regarding nodal size and tracer uptake may be appropriate, as relatively large nodes appear to represent a common finding at this LN station (31). Because many of the LNs assessed in this study were small, partial-volume effects (PVE) may influence SUV measurements (32). To mitigate this, SUVmax was selected as the primary quantitative metric, consistent with prior studies of LN imaging (33-35). SUVmax is readily obtainable, highly reproducible, and less dependent on precise ROI delineation (36). However, a limitation of this metric should be acknowledged. Because SUVmax represents a single-voxel measurement, it is inherently sensitive to image noise (36,37). While other metrics, such as SUVpeak, offer theoretical advantages by reducing noise sensitivity through averaging the highest uptake values within a defined volume (typically a 1 cm3 sphere), applying SUVpeak to our cohort posed a methodological challenge (37,38). Since many of the evaluated LNs were sub-centimeter in size, a standard 1 cm³ SUVpeak sphere would inevitably encompass surrounding non-tumorous background tissues. This would artificially lower the measured uptake values and paradoxically exacerbate the PVE we aimed to avoid. Similarly, SUVmean remains dependent on subjective boundary delineation, which suffers from significant inter-observer variability for such tiny nodes (21). Therefore, although we retained SUVmax to avoid these specific methodological pitfalls for small lesions, future studies incorporating novel noise-reduction reconstruction algorithms or utilizing optimized volumetric metrics may improve the robustness of quantitative LN assessment (39,40). Given that our study included data acquired from both PET/CT (n=29) and PET/MR (n=93) systems, potential differences in scanner performance could affect SUV comparability, especially in small LNs. To minimize inter-scanner variability, all examinations were performed using a standardized PET imaging protocol at our center. In addition, SUVmax values of each LN station were compared between PET/CT and PET/MR via the Mann-Whitney U test. The results showed no significant differences in SUVmax across LN stations between the two modalities (Table S2). Besides, the LBR was introduced to normalize uptake values and further reduce the potential impact of inter-scanner variability. We further sought to investigate the potential factors contributing to these observed variations in LNs uptake patterns. CXCR4/CXCL12 axis regulates multiple inflammatory pathways including the PLC, PI3K/Akt, JAK/STAT, and NF-κB signaling pathways and involves local immune responses (41-43). 68Ga-pentixafor is avidly uptaken by leukocyte subpopulations and polarized macrophages, with the highest uptake observed in T-cells and B-cells compared to neutrophils in vitro (44). We hypothesized that 68Ga-pentixafor uptake of LNs reflects local immune activation. Therefore, we investigated correlations between 68Ga-pentixafor uptake and inflammatory indices. For LN stations 12p and 8a, both of which demonstrated high positivity rates for 68Ga-pentixafor uptake, no significant correlation was found between LBR of them and inflammatory indices, implying localized 68Ga-pentixafor uptake independent of systemic inflammation. Whether this uptake is nonspecific requires further validation. Regarding other inflammatory biomarkers, limited by retrospective study, interleukin 6 (IL-6), CRP, and IL-2R were only available in small cohort, so the correlation analysis was not performed. Furthermore, activation of the CXCL12-CXCR4 pathway is associated with viral hepatitis, as lymphocytes expressing CXCR4 are recruited to the liver through CXCL12 signaling, which is regulated within hepatic tissue (45-47). Given that gastric LNs constitute a crucial component of the hepatic lymphatic drainage system, we investigated potential differences in viral hepatitis seropositivity (HBsAg and HBcAb) between 68Ga-pentixafor uptake-negative and uptake-positive groups across various LN station groups including perigastric, near-extragastric, far-extragastric, and distant LNs (48). No statistically significant differences were observed, indicating that 68Ga-pentixafor PET interpretation may not require special consideration of HBV status. However, these results should be interpreted with caution due to the relatively small number of HBsAg-positive cases (n=6), which may constrain the ability to detect subtle associations. Additionally, we did not assess HBV DNA levels, which might provide further insights into the relationship between viral activity and CXCR4 expression. Regarding liver function test, the vast majority of patients (approximately 90%) exhibited completely normal liver function, with only a small subset showing mild elevations in hepatic inflammation markers. Intriguingly, weak associations between the LBR in portal-area LNs (LN station 9, 12a, 12b, and 12p) and liver function test parameters raise the possibility of specialized immune-metabolic crosstalk between hepatic function and regional lymphatics. These observations are preliminary and require validation in larger prospective studies. Besides, considering patients with distant LNs involvement requires more aggressive treatment in gastric MALT lymphoma, the understanding of physiological uptake characteristics of distant gastric LNs and clinical relevance is critical to interpret the uptake for distant LNs accurately (10). The comparisons of the laboratory parameters between groups with and without distant LNs uptake revealed that ALT level (P=0.038) was higher in group with distant LNs uptake but within the normal reference range, suggesting limited clinical relevance of this finding. Besides, other factors were not significantly different. These observations reinforce that PET interpretation of distant LNs should primarily rely on established patterns of physiological and pathological tracer uptake rather than minor laboratory variations. Several limitations should be acknowledged in this study. First, the retrospective design constrained our ability to systematically collect certain clinically relevant data, such as infection state of Helicobacter pylori (H. pylori) and comprehensive inflammatory biomarkers. H. pylori infection would stimulate the expression of CXCR4 in immune cells and elevated inflammatory cytokines levels in infected patients (49,50). Moreover, the development of MALT lymphoma is associated with the chronic infection of H. pylori (10). Further prospective studies should specifically investigate the correlation between H. pylori infection and uptake patterns of gastric LN stations on 68Ga-pentixafor PET. Second, the inability to obtain histological confirmation of 68Ga-pentixafor-avid LNs represents a significant limitation, as this precludes definitive characterization of the cellular basis for tracer uptake. Third, this study exclusively included patients with hyperaldosteronism without malignant disease, rather than a truly normal population, which may limit the generalizability of the findings. Besides, although this design enabled characterization of physiological LNs uptake patterns to aid image interpretation, it precluded the establishment of cut-off values for differentiating physiological from metastatic LN uptake. Fourth, the scans were performed using both PET/CT and PET/MR scanners. Although our analyses showed no significant differences in LNs or blood pool uptake between the two modalities, and we further corrected for potential inter-scanner variability using the LBR, residual differences in scanner performance, resolution, or calibration may still influence quantitative measurements. Therefore, the inclusion of multiple scanner types remains a potential source of variability and should be considered when interpreting the results. Finally, as detailed earlier, relying solely on SUVmax, while mitigating the biases of SUVpeak and SUVmean in small lesions, leaves our measurements susceptible to single-voxel noise. Overall, future prospective studies incorporating histological validation, standardized protocols, and advanced noise-reduction algorithms are warranted to verify our findings. Conclusions We summarized the physiological uptake patterns of gastric LN stations using 68Ga-pentixafor PET and established the reference ranges of SUVmax and LBR in non-malignant conditions. However, due to the limited sample size and its retrospective nature, future multicenter studies with larger, more diverse patient populations are needed to validate these preliminary findings. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the ethics board of West China Hospital, Sichuan University (Ethics No. 2020[1670]). Informed consent was waived in this retrospective study. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-aw-2367/rc Funding: This work was supported by the National Key R&D Program of China (Grant No. 2023YFC2414201-1, to M.S.), and the National Natural Science Foundation of China (Grant No. 82202211, to H.W.). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2025-aw-2367/coif). M.S. received funding from the National Key R&D Program of China (Grant No. 2023YFC2414201-1). H.W. received funding from the National Natural Science Foundation of China (Grant No. 82202211). The other authors have no conflicts of interest to declare. Data Sharing Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-aw-2367/dss References Associated Data Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-aw-2367/dss